Summary of findings for the main comparison. Recompression therapy for decompression illness.
| Recompression therapy for decompression illness | ||||||
| Patient or population: patients with decompression illness Settings: patients referred to a hyperbaric facility for recompression Intervention: tenoxicam (adjunctive therapy) | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| placebo | tenoxicam | |||||
| Need for second recompression Simple count Follow‐up: mean 6 weeks1 | Study population | RR 0.64 (0.46 to 0.86) | 180 (1 study) | ⊕⊕⊕⊕ high | ||
| 611 per 1000 | 391 per 1000 (287 to 501) | |||||
| Low risk population | ||||||
| 400 per 1000 | 256 per 1000 (188 to 328) | |||||
| High risk population | ||||||
| 800 per 1000 | 512 per 1000 (376 to 656) | |||||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 All patients reviewed at discharge
2 Assumed risks estimated by authors from the literature review and clinical experience